Isenberg D
Centre for Rheumatology, Department of Medicine, UCL London, UK.
Lupus. 2004;13(11):881-5. doi: 10.1191/0961203304lu2028oa.
The presence of antibodies to dsDNA has been a criterion for systemic lupus erythematosus (SLE) in each of three attempts to classify the disease that have been undertaken by the American College of Rheumatology. The generally good specificity of the test, the fact that it is widely available and often undertaken by an enzyme linked immunosorbent assay (ELISA) which is relatively cheap and easy to perform have encouraged its continued presence in the list of lupus criteria. The detection of anti-dsDNA antibodies is not, however, straightforward and the real significance of the presence of these antibodies, their true specificity (or otherwise), the question of whether they are truly linked to disease pathogenicity and how accurately they reflect disease activity are all questions that have been posed in the past 20 years.
美国风湿病学会进行的三次系统性红斑狼疮(SLE)疾病分类尝试中,抗双链DNA抗体的存在一直是SLE的一项标准。该检测通常具有良好的特异性,且广泛可用,常通过相对便宜且易于操作的酶联免疫吸附测定(ELISA)进行,这些因素促使其继续被列入狼疮诊断标准清单。然而,抗双链DNA抗体的检测并非简单直接,在过去20年里,这些抗体存在的真正意义、其真正的特异性(或其他情况)、它们是否真的与疾病致病性相关以及它们能多准确地反映疾病活动等问题一直存在。